GAMMA Investing LLC Has $120.91 Million Position in Hologic, Inc. (NASDAQ:HOLX)

GAMMA Investing LLC grew its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4,467.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 195,749 shares of the medical equipment provider's stock after purchasing an additional 191,463 shares during the quarter. GAMMA Investing LLC owned approximately 0.09% of Hologic worth $120,910,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of HOLX. Norges Bank bought a new position in shares of Hologic during the 4th quarter valued at about $133,414,000. Boston Partners lifted its stake in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares during the period. Champlain Investment Partners LLC purchased a new position in shares of Hologic in the 4th quarter valued at approximately $79,291,000. Northern Trust Corp lifted its stake in shares of Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after purchasing an additional 668,086 shares during the period. Finally, Invesco Ltd. raised its stake in Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.88% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HOLX has been the subject of several research analyst reports. Morgan Stanley cut their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Royal Bank of Canada reduced their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Finally, Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Stock Performance

NASDAQ HOLX traded up $0.46 during trading hours on Thursday, hitting $63.03. 386,362 shares of the stock were exchanged, compared to its average volume of 2,276,138. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average of $58.19 and a 200 day moving average of $65.65. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a market cap of $14.05 billion, a price-to-earnings ratio of 19.85, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company's revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted $1.03 EPS. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.